Semax is a synthetic seven-amino-acid peptide modeled on a fragment of the hormone ACTH. It is a registered drug in Russia, and many of the studies FDA found were published only in Russian.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no United States Pharmacopeia or European Pharmacopoeia monograph for it.1 Human data are limited to small, mostly uncontrolled or incompletely reported studies. FDA found insufficient evidence that it works for the uses it evaluated and insufficient information to describe its safety.1 FDA staff recommended against adding Semax to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.1,5,6
Semax at a glance
What it is
A synthetic peptide of seven amino acids, designed from a fragment of adrenocorticotropic hormone (ACTH) without that hormone’s hormonal effects.1
FDA status
Not FDA-approved. FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, Semax free base is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,5,6
Human evidence
Small studies and meeting abstracts, mostly without a control group. The one pain study FDA reviewed in detail found that Semax did not resolve pain for most participants.1
Evidence strength
Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned
What is Semax?
Semax is a synthetic peptide made of seven amino acids. FDA’s briefing describes it as an analog of a fragment of adrenocorticotropic hormone (ACTH) that lacks the hormone’s effects on the adrenal glands and skin pigment but keeps effects on the nervous system.1
Semax is a registered drug in Russia. There is no monograph for it in the European, Japanese or International Pharmacopoeia.1
FDA could not determine how widely Semax has been used in U.S. compounding. It found Semax widely marketed by wellness and concierge clinics and online retailers for conditions ranging from anxiety and memory to stroke and nerve damage, often without saying whether products were compounded.1
How is Semax thought to work?
How Semax works is poorly understood. In rodents it has been reported to protect nerve cells, reduce clotting, relieve pain, and produce antidepressant-like and anti-anxiety-like effects.1
FDA flags two concerns from these studies. Semax’s possible anti-clotting effect raises a bleeding risk, and in mice it increased the brain’s dopamine response to amphetamine, a pattern FDA associates with drugs of abuse.1
FDA found no studies in people showing how Semax is absorbed or handled by the body.1
What do human studies show?
FDA evaluated Semax for reduced blood flow to the brain (cerebral ischemia), migraine and trigeminal neuralgia, and concluded there is insufficient evidence that it works for any of them.1
The only study FDA reviewed in detail for pain was a small 1996 study without a control group or blinding. A minority of migraine patients reported relief, and the authors themselves concluded that Semax did not show pain-relieving activity on its own in trigeminal neuralgia.1
For cerebral ischemia, FDA found only a meeting abstract that did not report clinical outcomes. Other studies were published in Russian without full English versions, so FDA did not consider them.1
Across the reports FDA found, Semax had been given to between about 100 and 115 adults and to 451 children. Most reports did not discuss side effects, and one reported none.1
FDA’s adverse-event database search through December 2025 found one consumer report, of eye pain and burning with hospitalization in 2024, after using a Semax product.1
What the evidence base contains
Small, short, or incompletely reported human study A 1996 study without a control group or blinding in 37 adults with migraine or facial nerve pain. Four of 12 migraine patients reported that their headache stopped, and patients with typical trigeminal neuralgia showed no change in pain.1
Small, short, or incompletely reported human study A 2002 meeting abstract on people with chronic reduced blood flow to the brain that did not report the number of patients or clinical outcomes.1
Small, short, or incompletely reported human study Other reports FDA found in healthy adults, adults with peptic ulcer, and children with depression or tics. Several are meeting abstracts, most did not discuss side effects, and in some Semax was given alongside other treatments.1
Animal or laboratory research Rodent studies reporting nerve-protective, anti-clotting, pain-relieving and antidepressant-like effects through mechanisms FDA describes as poorly understood.1
No. FDA’s May 2026 evaluation states that neither Semax free base nor Semax acetate is a component of an FDA-approved drug and that there is no United States Pharmacopeia monograph for either.1
Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.5
FDA staff evaluated both forms of Semax for that list and recommended against adding either. They cited missing chemical characterization data, insufficient evidence of effectiveness, safety concerns including bleeding risk and possible immune reactions, and existing FDA-approved treatments for most of these conditions.1
FDA’s compounding safety-risk page, last updated April 22, 2026, lists Semax among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.3
HHS’s policy document states that Semax was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.3,6
FDA’s Pharmacy Compounding Advisory Committee discussed Semax on July 24, 2026. HHS’s policy document states that the committee voted in favor of both forms, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,2,6
On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.5,6
Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For Semax, unlike the other five, the policy covers only the free-base form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.6
HHS and FDA staff weigh the same record differently. HHS’s policy document says newer certificates supply the quality test results FDA staff found missing, that use is now documented, and that the human record FDA staff compiled covers several hundred people with no reported adverse outcome. FDA staff had concluded that the clinical information was insufficient to characterize Semax’s safety.1,6
The policy does not make Semax an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.5,6
Timeline
A small study of Semax in adults with migraine and facial nerve pain is published, the main pain study FDA later reviewed.1
Semax is placed in FDA’s Category 2 of nominated compounding substances that may present significant safety risks, according to HHS’s policy document.6
A Federal Register notice announces the July advisory-committee meeting that will discuss Semax and opens a public comment docket.4
Semax leaves Category 2, according to HHS’s policy document. FDA’s compounding safety-risk page, as last updated that day, lists it among withdrawn nominations.3,6
FDA staff date their evaluation recommending that Semax not be added to the 503A bulks list.1
HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists Semax among six peptide substances used in compounding.5,6
What is still unknown?
Whether Semax benefits people for any condition: FDA found no adequately reported controlled trial.1
Its safety, including bleeding risk and abuse potential, and how it is absorbed in people.1
What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that the studies it found did not say which form they used.1
Whether FDA’s rulemaking will add Semax to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,5,6
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Semax: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Semax are the records PeptideScanner has selected and published, not every registration or paper about Semax. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists Semax free base among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make Semax an FDA-approved drug.↗↗↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Two selected reports examine Semax alongside care for ischemic stroke. They concern specific stroke populations and do not establish effects in healthy people or other indications.↗↗
What the reviewed sources report
The authors reported better functional recovery measures with Semax-containing care. Unclear allocation and masking, concurrent rehabilitation and incomplete harms reporting limit causal conclusions.↗↗
What remains unresolved?
Can adequately randomized, masked studies reproduce the reported functional effects?↗↗
What do complete reports establish about missing outcomes, concomitant care and safety?↗↗
Two selected reports examine Semax alongside care for ischemic stroke. They concern specific stroke populations and do not establish effects in healthy people or other indications.12
Bottom line from this bounded source set
The authors reported better functional recovery measures with Semax-containing care. Unclear allocation and masking, concurrent rehabilitation and incomplete harms reporting limit causal conclusions.12
Reviewed study record
Stroke rehabilitation and functional measures
Design
Patients in early and late rehabilitation groups were subdivided according to whether they received Semax.1
Population
The report included 110 people after ischemic stroke.1
Outcomes reported
The authors reported higher BDNF levels and better Barthel functional scores with Semax-containing care; rehabilitation timing also affected outcomes.1
Limitations
The abstract does not establish random allocation or masking and does not provide a detailed harms account. Concurrent rehabilitation and group differences may confound the findings.1
Reviewed study record
Acute ischemic stroke
Design
A clinical and electrophysiological comparison assessed Semax added to conventional intensive care.2
Population
Thirty Semax-treated patients were compared with eighty conventionally treated patients with reportedly similar stroke severity and lesion location.2
Outcomes reported
The authors described faster neurological recovery, particularly in motor measures.2
Limitations
The abstract does not clearly describe randomization, masking, a prespecified primary endpoint or adverse events. Unequal groups and combined care limit causal interpretation.2
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.17116/jnevro20181183261-68. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
The 2026 assessment did not establish the nominated uses
FDA’s briefing found insufficient evidence for cerebral ischemia, migraine and trigeminal neuralgia. The reviewed clinical references had limited methods and outcome information; this is the agency’s scoped assessment. FDA PDF pp. 29 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
Uncontrolled symptom reports have limited interpretability
For migraine and trigeminal neuralgia, FDA described small uncontrolled studies with unclear rating scales and incomplete reporting. Before-and-after changes alone cannot distinguish treatment effects from other explanations. FDA PDF pp. 26, 28 ↗
Nonclinical effects are not established clinical benefits
The briefing discusses neurological and other effects in rodents but poorly understood mechanisms and missing toxicology relevant to the proposed subcutaneous route. Those findings cannot be promoted into demonstrated human efficacy. FDA PDF pp. 37 ↗
Form and safety reporting remain important gaps
Clinical references often did not specify free base versus salt, and many did not discuss safety. FDA raised questions about bleeding and injectable-product immunogenicity; these are concerns requiring evidence, not quantified risks established by these reports. FDA PDF pp. 37, 41 ↗
What remains to be checked
Check subsequent advisory records and any final FDA action separately from the staff briefing.
Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Primary human administration reports for the specified molecule; other peptides, preclinical experiments and secondary reviews are separate.
207 retrieved · 2 included · 0 excluded · 205 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"semax"[Title/Abstract]
Regulator and trial-registry searches and non-indexed reports require separate reconciliation.
Full-text appraisal, study-family linkage and citation follow-up remain open.
Showing 25 of 207 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 29798983 — include: Selected human report; abstract and record metadata reviewed. Study families: Semax-stroke-rehabilitation-2018.
PubMed 11517472 — include: Selected human report; abstract and record metadata reviewed. Study families: Semax-stroke-2001.
PubMed 42559144 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42195624 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42074872 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42021992 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 41490200 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42366656 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 41004910 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 40692165 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 41479572 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 41179234 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 41171324 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 40650034 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 40496623 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 39604801 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 39767736 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 39442746 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 39418522 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 37510287 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 36828803 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 36553646 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 35853762 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 35080861 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 36083821 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Semax?
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists Semax free base among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make Semax an FDA-approved drug.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
42
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 42 dated records
We added a plain-language reader guide with cited answers, re-checked FDA’s Semax briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists Semax free base. FDA has not issued a final 503A rule.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.
Selected records span November 15, 2006 to July 24, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.↗
PubMed lists PMID 18204410 in CNS spectrums as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-01 (month precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 23652441 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-08 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 23821053 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-03 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 32737723 in Bulletin of experimental biology and medicine as Journal Article, with publication-date metadata of 2020-08-01 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 22096989 in Bioorganicheskaia khimiia as Journal Article, with publication-date metadata of 2011 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 15344653 in Bioorganicheskaia khimiia as English Abstract, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 16523722 in Bioorganicheskaia khimiia as English Abstract, Journal Article, with publication-date metadata of 2006 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 17278839 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 18018999 in Bulletin of experimental biology and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 19145359 in Bulletin of experimental biology and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗